Pharmaceuticals News and Research

RSS

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting.

7 Jun 2010

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used in combination with Roche's investigational antibody, pertuzumab.

7 Jun 2010

ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010

ChemGenex Pharmaceuticals Limited announced that positive safety findings from a combined analysis of two clinical trials for its lead product candidate, OMAPRO™ (omacetaxine mepesuccinate), were presented today during a poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

7 Jun 2010

Research focuses on art, pharmaceutical drugs and the environment

Providing solutions to any current problem is the mission of analytical chemistry, according to Ms Rosa Alonso, director of the Farmartem Research Group at the University of the Basque Country. The group's name says it all with respect to the wide range of these problems - Farmartem: the abbreviation in Spanish of pharmaceuticals, art and the environment (f-rmacos, arte, medio ambiente).

5 Jun 2010

Media increases effectiveness of direct-to-patient marketing approaches

All too often, study sponsors provide research sites with an advertising budget to promote their clinical trial to patients, and yet the majority of research sites require support or guidance on where and when to invest these advertising dollars. This support comes from trained and experienced advertising professionals who are experts in knowing the best way to maximize advertising budgets, and optimize the return on advertising investment.

5 Jun 2010

MediciGlobal survey identifies strategies followed in patient recruitment for clinical trials

Much is written about how patient recruitment can either accelerate or undermine clinical trial success. But how is the industry approaching patient recruitment in general? Do companies plan proactively? Who is involved in the process and what decisions do they make in order to effectively plan for success?

5 Jun 2010

Burden of substance abuse casts tragic shadow on the lives of many young people: Report

On an average day, 508,000 adolescents aged 12-17 in the United States drink alcohol; 641,000 use illicit drugs; and more than 1 million smoke cigarettes, according to a national survey sponsored by the Substance Abuse and Mental Health Services Administration.

5 Jun 2010

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

5 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

BMJ report questions WHO advisors' ties to pharmaceutical industry

"Key scientists behind World Health Organization advice on stockpiling of pandemic flu drugs had financial ties with companies which stood to profit," according to a joint investigation by BMJ in collaboration with the Bureau of Investigative Journalism, BBC News reports (6/4).

5 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes to remain convertible through July 6, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 (the "notes") are convertible at the option of the holders and will remain convertible at least through July 6, 2010, as provided for in the Indenture governing the notes.

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

5 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

Mylan subsidiary receives FDA approval for generic version of Neurontin Tablets

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Gabapentin Tablets USP, 600 mg and 800 mg, the generic version of Pfizer's Neurontin Tablets for the treatment of postherpetic neuralgia, a complication of shingles.

5 Jun 2010

Cardinal Health and UW collaborate to advance use of molecular imaging in clinical investigations and trials

Cardinal Health and the University of Washington (UW) today announced an innovative public-private collaboration designed to advance the use of molecular imaging in clinical investigations and trials.

4 Jun 2010

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

4 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Pharmaceuticals News and Research

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010

Research focuses on art, pharmaceutical drugs and the environment

Media increases effectiveness of direct-to-patient marketing approaches

MediciGlobal survey identifies strategies followed in patient recruitment for clinical trials

Burden of substance abuse casts tragic shadow on the lives of many young people: Report

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

New clinical research findings on oncology to be highlighted at ASCO 2010

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

BMJ report questions WHO advisors' ties to pharmaceutical industry

OSI Pharmaceuticals' 2% Senior Subordinated Notes to remain convertible through July 6, 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Mylan subsidiary receives FDA approval for generic version of Neurontin Tablets

Cardinal Health and UW collaborate to advance use of molecular imaging in clinical investigations and trials

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence